Skip to content

Study · Systematic review · 2021

2 results

Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.

Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, Fujiwara R, Takahashi H, Murata K

Heart failure reviews1 Sept 2021Cited by 22 (Europe PMC)

PMID32080782 (opens in a new tab)DOI10.1007/s10741-020-09936-w (opens in a new tab)PepBankPUB-32080782
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a network meta-analysis found that liraglutide significantly improved left ventricular diastolic function (lower E/e') versus placebo.

    In plain wordsIn adults with type 2 diabetes, pooled trials found liraglutide improved heart relaxation more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseLeft ventricular diastolic function (E/e') versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    SMD, E/e'
    −0.65 SMD
    liraglutide vs placebo

    Source sentences

    Summary
    Compared with placebo, liraglutide was the only drug that caused a significant improvement in left ventricular diastolic function (SMD, - 0.65; 95% CI, - 1.23 to - 0.08).
    2 context sentences
    Summary · context
    RCTs that assessed the effects on left ventricular diastolic function of OADs and GLP-1RAs in patients with type 2 diabetes were included.
    Summary · context
    Eight RCTs (592 patients) identified in a literature search met the eligibility criteria for this study and were included in the network meta-analysis.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a network meta-analysis found that liraglutide alone significantly improved left ventricular diastolic function compared with oral antidiabetic drugs.

    In plain wordsIn adults with type 2 diabetes, pooled trials found liraglutide improved heart relaxation more than oral diabetes drugs.

    Peptide
    Liraglutide
    Outcome
    DecreaseLeft ventricular diastolic function (E/e') versus oral antidiabetic drugs
    Study

    n: not reported in source

    Comparator
    Oral antidiabetic drugs (sitagliptin, linagliptin, pioglitazone, rosiglitazone, voglibose, glimepiride)
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, when the effects on left ventricular diastolic function were evaluated across drugs, liraglutide alone caused a significant improvement in left ventricular diastolic function compared with OADs (sitagliptin, linagliptin, pioglitazone, rosiglitazone, voglibose, and glimepiride).
    2 context sentences
    Summary · context
    RCTs that assessed the effects on left ventricular diastolic function of OADs and GLP-1RAs in patients with type 2 diabetes were included.
    Summary · context
    Eight RCTs (592 patients) identified in a literature search met the eligibility criteria for this study and were included in the network meta-analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.